$1.6
1.88%
Downside
Day's Volatility :13.74%
Upside
12.09%
27.5%
Downside
52 Weeks Volatility :89.11%
Upside
84.98%
Period | Pacific Biosciences Of California, Inc. | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -0.31% | -7.2% | 0.0% |
6 Months | -21.04% | -3.1% | 0.0% |
1 Year | -81.01% | 10.6% | 0.0% |
3 Years | -94.1% | 6.1% | -25.6% |
Market Capitalization | 508.0M |
Book Value | $1.66 |
Earnings Per Share (EPS) | -1.46 |
PEG Ratio | -0.17 |
Wall Street Target Price | 3.021 |
Profit Margin | -227.69% |
Operating Margin TTM | -140.13% |
Return On Assets TTM | -10.61% |
Return On Equity TTM | -64.8% |
Revenue TTM | 173.1M |
Revenue Per Share TTM | 0.64 |
Quarterly Revenue Growth YOY | -28.199999999999996% |
Gross Profit TTM | 53.5M |
EBITDA | -242.9M |
Diluted Eps TTM | -1.46 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.82 |
EPS Estimate Next Year | -0.64 |
EPS Estimate Current Quarter | -0.22 |
EPS Estimate Next Quarter | -0.2 |
What analysts predicted
Upside of 88.8%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 78.6M | ↓ 15.88% |
Net Income | -102.6M | ↑ 11.25% |
Net Profit Margin | -130.44% | ↓ 31.81% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 90.9M | ↑ 15.6% |
Net Income | -77.8M | ↓ 24.12% |
Net Profit Margin | -85.62% | ↑ 44.82% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 78.9M | ↓ 13.2% |
Net Income | 29.4M | ↓ 137.78% |
Net Profit Margin | 37.27% | ↑ 122.89% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 130.5M | ↑ 65.43% |
Net Income | -181.2M | ↓ 716.34% |
Net Profit Margin | -138.85% | ↓ 176.12% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 128.3M | ↓ 1.69% |
Net Income | -296.9M | ↑ 63.85% |
Net Profit Margin | -231.43% | ↓ 92.58% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 200.5M | ↑ 56.29% |
Net Income | -306.7M | ↑ 3.3% |
Net Profit Margin | -152.97% | ↑ 78.46% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 47.6M | ↑ 22.3% |
Net Income | -69.8M | ↓ 13.94% |
Net Profit Margin | -146.79% | ↑ 61.82% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 55.7M | ↑ 17.06% |
Net Income | -66.9M | ↓ 4.24% |
Net Profit Margin | -120.07% | ↑ 26.72% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 58.4M | ↑ 4.79% |
Net Income | -82.0M | ↑ 22.65% |
Net Profit Margin | -140.55% | ↓ 20.48% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 38.8M | ↓ 33.5% |
Net Income | -78.2M | ↓ 4.68% |
Net Profit Margin | -201.44% | ↓ 60.89% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Revenue | 36.0M | ↓ 7.21% |
Net Income | -173.3M | ↑ 121.7% |
Net Profit Margin | -481.27% | ↓ 279.83% |
Q3 FY24 | Q/Q Change | |
---|---|---|
Revenue | 40.0M | ↑ 10.98% |
Net Income | -60.7M | ↓ 64.96% |
Net Profit Margin | -151.94% | ↑ 329.33% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 170.3M | ↑ 18.18% |
Total Liabilities | 56.2M | ↓ 3.05% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 148.0M | ↓ 13.09% |
Total Liabilities | 93.1M | ↑ 65.56% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 414.0M | ↑ 179.74% |
Total Liabilities | 78.5M | ↓ 15.66% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 2.0B | ↑ 384.8% |
Total Liabilities | 1.2B | ↑ 1449.24% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 1.8B | ↓ 11.95% |
Total Liabilities | 1.2B | ↓ 0.97% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 1.7B | ↓ 1.19% |
Total Liabilities | 1.0B | ↓ 13.24% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 1.8B | ↓ 2.57% |
Total Liabilities | 1.2B | ↑ 0.11% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 1.9B | ↑ 2.75% |
Total Liabilities | 1.1B | ↓ 5.89% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 1.7B | ↓ 8.02% |
Total Liabilities | 1.0B | ↓ 7.92% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 1.7B | ↓ 4.36% |
Total Liabilities | 1.0B | ↓ 2.28% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 1.5B | ↓ 9.61% |
Total Liabilities | 1.0B | ↓ 0.4% |
Q3 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 1.5B | ↓ 3.94% |
Total Liabilities | 996.9M | ↓ 1.95% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -66.4M | ↓ 1.61% |
Investing Cash Flow | -38.4M | ↑ 2379.99% |
Financing Cash Flow | 107.2M | ↑ 55.77% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -78.3M | ↑ 17.89% |
Investing Cash Flow | 62.0M | ↓ 261.52% |
Financing Cash Flow | 26.5M | ↓ 75.23% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 19.5M | ↓ 124.9% |
Investing Cash Flow | -219.3M | ↓ 453.48% |
Financing Cash Flow | 251.8M | ↑ 848.62% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -111.2M | ↓ 670.07% |
Investing Cash Flow | -678.5M | ↑ 209.38% |
Financing Cash Flow | 1.2B | ↑ 364.42% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -263.2M | ↑ 136.74% |
Investing Cash Flow | 116.1M | ↓ 117.11% |
Financing Cash Flow | 9.6M | ↓ 99.18% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -41.7M | ↓ 55.92% |
Investing Cash Flow | -98.6M | ↑ 35.89% |
Financing Cash Flow | -4.7M | ↓ 102.41% |
Sell
Neutral
Buy
Pacific Biosciences Of California, Inc. is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Pacific Biosciences Of California, Inc. | -16.05% | -21.04% | -81.01% | -94.1% | -65.62% |
Stryker Corporation | 8.44% | 16.55% | 35.27% | 48.85% | 90.23% |
Boston Scientific Corp. | 0.66% | 16.53% | 60.08% | 109.06% | 105.7% |
Edwards Lifesciences Corp. | -1.04% | -23.98% | 1.29% | -42.75% | -16.13% |
Abbott Laboratories | -1.69% | 11.35% | 16.42% | -9.89% | 37.55% |
Medtronic Plc | -2.52% | 1.87% | 17.08% | -25.72% | -21.32% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Pacific Biosciences Of California, Inc. | NA | NA | -0.17 | -0.82 | -0.65 | -0.11 | NA | 1.66 |
Stryker Corporation | 41.66 | 41.66 | 2.71 | 12.05 | 0.19 | 0.07 | 0.01 | 52.86 |
Boston Scientific Corp. | 73.61 | 73.61 | 1.61 | 2.46 | 0.09 | 0.05 | NA | 14.05 |
Edwards Lifesciences Corp. | 25.57 | 25.57 | 6.07 | 2.53 | 0.19 | 0.11 | NA | 16.18 |
Abbott Laboratories | 35.02 | 35.02 | 2.25 | 4.67 | 0.15 | 0.06 | 0.02 | 22.94 |
Medtronic Plc | 29.55 | 29.55 | 1.63 | 5.2 | 0.08 | 0.04 | 0.03 | 37.39 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Pacific Biosciences Of California, Inc. | Buy | $508.0M | -65.62% | NA | -227.69% |
Stryker Corporation | Buy | $146.1B | 90.23% | 41.66 | 16.34% |
Boston Scientific Corp. | Buy | $129.1B | 105.7% | 73.61 | 11.26% |
Edwards Lifesciences Corp. | Buy | $40.0B | -16.13% | 25.57 | 65.86% |
Abbott Laboratories | Buy | $201.0B | 37.55% | 35.02 | 13.99% |
Medtronic Plc | Buy | $110.3B | -21.32% | 29.55 | 12.06% |
Insights on Pacific Biosciences Of California, Inc.
Revenue is up for the last 2 quarters, 36.01M → 39.96M (in $), with an average increase of 9.9% per quarter
Netprofit is up for the last 2 quarters, -173.31M → -60.72M (in $), with an average increase of 185.4% per quarter
In the last 1 year, Boston Scientific Corp. has given 60.1% return, outperforming this stock by 141.1%
In the last 3 years, Boston Scientific Corp. has given 109.1% return, outperforming this stock by 203.2%
ARK Investment Management LLC
Vanguard Group Inc
BlackRock Inc
Madrone Advisors LLC
Edmond de Rothschild Holding S.A.
Sumitomo Mitsui Trust Group Inc
pacbio develops comprehensive solutions for scientists that propel the field of genomics, improve science and research, and create positive impact globally. we provide sophisticated genomic analysis systems that deliver invaluable insights for scientists who strive to resolve complex genetic challenges. our strength comes from the dedication of our people, who are fueled by a desire to effect real, positive change. with a focus on the future and an experienced, passionate team, we are motivated to continue to redefine what is possible in genomics.
Organization | Pacific Biosciences Of California, Inc. |
Employees | 796 |
CEO | Mr. Christian O. Henry M.B.A. |
Industry | Health Technology |
Cactus Acquisition Corp 1 Ltd
$1.60
-14.02%
Rigel Resource Acquisition Corp
$1.60
-14.02%
Fortune Rise Acquisition Corp
$1.60
-14.02%
P.a.m. Transportation Svcs
$1.60
-14.02%
Blockchain Coinvestors Acquisition Corp.
$1.60
-14.02%
Onyx Acquisition Co. I
$1.60
-14.02%
Perception Capital Corp Iv
$1.60
-14.02%
Bny Mellon Ultra Short Income Etf
$1.60
-14.02%
Evgo Inc Cl A
$1.60
-14.02%